Systemic Sclerosis (Scleroderma)

Systemic sclerosis (SSc) is a rare autoimmune disease characterized by microvascular damage, immune activation, and fibrosis of skin and internal organs. It ranges from limited cutaneous involvement to aggressive diffuse disease with lung, kidney, and cardiac complications. Early detection of organ involvement is vital.

Types

• Limited cutaneous SSc (lcSSc): Skin thickening distal to elbows/knees, face involvement; often associated with CREST.
• Diffuse cutaneous SSc (dcSSc): Widespread skin thickening including trunk, rapid onset, higher risk of organ involvement.
• SSc sine scleroderma: Internal organ fibrosis without obvious skin thickening.

Symptoms & Signs

• Raynaud phenomenon (often first symptom)
• Puffy fingers progressing to skin thickening, digital ulcers
• Telangiectasias, calcinosis, hypo/hyperpigmentation
• Joint contractures, tendon friction rubs
• Gastroesophageal reflux, dysphagia, malabsorption
• Dyspnea from interstitial lung disease (ILD) or pulmonary arterial hypertension (PAH)
• Renal crisis: abrupt hypertension, renal failure
• Cardiac arrhythmias, myocarditis, pericardial effusion

Diagnosis

• Autoantibodies: ANA, anti-centromere (lcSSc), anti-Scl-70/topoisomerase (dcSSc), anti-RNA polymerase III (renal crisis risk)
• Nailfold capillaroscopy for microvascular changes
• Pulmonary function tests (PFTs) and high-resolution CT for ILD
• Echocardiogram for PAH screening (annually)
• GI studies (manometry, gastric emptying) if symptomatic
• Renal labs, urinalysis, blood pressure monitoring

Treatment & Management

Vascular Care

• Raynaud management: keep warm, stop smoking, calcium channel blockers, PDE5 inhibitors, topical nitrates, botulinum toxin injections
• PAH: endothelin receptor antagonists, PDE5 inhibitors, prostacyclin analogues, soluble guanylate cyclase stimulators

Skin & Fibrosis

• Immunosuppressants: mycophenolate mofetil, methotrexate, cyclophosphamide
• ILD treatment: mycophenolate, cyclophosphamide, nintedanib, tocilizumab for inflammatory phenotype
• Physical/occupational therapy to maintain range of motion, prevent contractures

GI Management

• Proton pump inhibitors, prokinetics, low-FODMAP diet for SIBO
• Nutritional support, vitamin supplementation, pancreatic enzymes if malabsorption

Renal Crisis Prevention

• Monitor BP closely, especially in early dcSSc
• ACE inhibitors immediately if crisis suspected
• Avoid high-dose steroids when possible

Additional Support

• Pain management, antidepressants/anxiolytics
• Wound care for digital ulcers, consider prostacyclin infusions
• Vaccinations and infection prophylaxis during immunosuppression

Living with Systemic Sclerosis

• Track Raynaud attacks, skin changes, breathing, GI symptoms, and BP
• Use moisturizing routines, protect hands, and practice stretching exercises
• Seek mental health support—SSc can be isolating
• Coordinate care among rheumatology, pulmonology, cardiology, nephrology, dermatology, gastroenterology

Complications

• Pulmonary fibrosis or PAH leading to respiratory failure
• Scleroderma renal crisis
• Severe GI dysmotility causing malnutrition
• Cardiac arrhythmias, heart failure
• Digital ulcers, infections, amputations

Research & Future Directions

Research explores antifibrotic agents, immune cell targeting, and biomarkers predicting which patients will develop aggressive organ involvement.

Experimental & Emerging Treatments

• Autologous Hematopoietic Stem Cell Transplant: Offers long-term remission in severe dcSSc but carries significant toxicity.
• Anti-TGF-β & Anti-CTGF Agents: Target central fibrotic pathways (e.g., fresolimumab, pamrevlumab).
• JAK Inhibitors & BTK Inhibitors: Under investigation for inflammatory and fibrotic manifestations.
• Microbiome & Gut Interventions: Trials explore whether modulating intestinal dysbiosis can reduce GI symptoms and systemic inflammation.

Track Systemic Sclerosis with Diagnoza.care

Protect Organs & Quality of Life – Log Raynaud episodes, skin scores, lung function, GI symptoms, labs, medications, and specialist visits, capture side effects, and let the AI companion flag trends that need faster evaluation.

---

Medical Disclaimer: Informational only. Follow guidance from your rheumatology and multidisciplinary team for monitoring and treatment decisions. Sources: European League Against Rheumatism (EULAR), American College of Rheumatology, Scleroderma Foundation